Endocrine Abstracts

Aims: Our aim is to retrospectively analyze the diagnosis of hyponatremia in the discharge sheets of a tertiary hospital during 5 years and its relationship with type 1 and 2 diabetes mellitus.Methods: Data from the MBDS (Minimum Basic Data Set) of the discharged patients from the Hospital Clínico San Carlos (Madrid) between the years 2005 to 2009 was analysed. The 5th Edition of the ICD-9-CM was used for the codification of the diagnoses and proced...

Tolvaptan (TV), an ADH V2-receptor blocker, is useful in treating SIADH-induced hyponatremia. Maximum aquaresis following 15 mg TV occurs on day 1, when excess body water is greatest. This can cause a sharp rise in natremia, and poses a risk of overcorrection. Our aim was to evaluate an initial dose of 7.5 mg.Methods: We studied 7 hospitalized patients with SIADH (4 females), median age 80 (57–95), with nadir natremias (Nap) ranging from ...

Isolated acquired hypoaldosteronism (HA) is considered to be a cause of hypovolemic hyponatremia (HH) with urinary sodium loss (UNaL) and hyperkalemia/upper-limit serum potassium (SK). However, some authors question the presentation of hyponatremia of these characteristics in the absence of Addison’s disease (AD).We present a series of patients with HA. Methods: Aretrospective study of 70 cases of HH with UNaL (UNa > 25 mmol/l) and SK ≥ 5 mmol/l or in...

Introduction: The contrast agents iopanoic acid and ipodate are potent inhibitors of thyroid function, reducing type I deodinase T3 generation, inhibiting thyroid liberation of T4 and T3, and T3 receptor binding, with off-label use in hyperthyroid emergencies. However, since the interruption of iopanoic acid production this year, neither agent is currently available in Spain.Case report: A 34-year-old male was ...